These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 22901132)
1. Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution. Inal A; Kaplan MA; Kucukoner M; Urakci Z; Karakus A; Isikdogan A Asian Pac J Cancer Prev; 2012; 13(5):1837-40. PubMed ID: 22901132 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G; Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571 [TBL] [Abstract][Full Text] [Related]
3. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. Hoang T; Dahlberg SE; Schiller JH; Johnson DH Lung Cancer; 2013 Jul; 81(1):47-52. PubMed ID: 23611404 [TBL] [Abstract][Full Text] [Related]
4. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015 [TBL] [Abstract][Full Text] [Related]
5. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Li CH; Liu MY; Liu W; Li DD; Cai L Asian Pac J Cancer Prev; 2014; 15(2):731-6. PubMed ID: 24568487 [TBL] [Abstract][Full Text] [Related]
6. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S; Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605 [TBL] [Abstract][Full Text] [Related]
7. Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer. Rosati G; Rossi A; Nicolella G; Panza N Anticancer Res; 2000; 20(3B):2229-33. PubMed ID: 10928183 [TBL] [Abstract][Full Text] [Related]
8. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911 [TBL] [Abstract][Full Text] [Related]
9. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer. Lv C; Ma Y; Wu N; Yan S; Zheng Q; Sun Y; Li S; Fang J; Yang Y World J Surg Oncol; 2013 Mar; 11():76. PubMed ID: 23517534 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160 [TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer. Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403 [TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens. Kocak M; Ozkan A; Mayadagli A; Parlak C; Bilici A; Seker M; Oven Ustaalioglu BB; Gumus M; Eren M; Karabulut SG; Oruc F Clin Lung Cancer; 2009 Mar; 10(2):124-9. PubMed ID: 19362956 [TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients. Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426 [TBL] [Abstract][Full Text] [Related]
16. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. Katakami N; Takiguchi Y; Yoshimori K; Isobe H; Bessho A; Yoshimura A; Niitani H J Thorac Oncol; 2006 Jun; 1(5):447-53. PubMed ID: 17409898 [TBL] [Abstract][Full Text] [Related]
17. Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. Natukula K; Jamil K; Pingali UR; Suresh Attili VS; Naidu Madireddy UR Asian Pac J Cancer Prev; 2013; 14(8):4661-6. PubMed ID: 24083721 [TBL] [Abstract][Full Text] [Related]
18. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer. Luo J; Leaw SJ; Xu Y; Zheng D Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668 [TBL] [Abstract][Full Text] [Related]
19. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients. Chen LK; Liang Y; Yang QY; Xu F; Zhou NN; Xu GC; Liu GZ; Wei WD Asian Pac J Cancer Prev; 2012; 13(5):1863-7. PubMed ID: 22901137 [TBL] [Abstract][Full Text] [Related]